Marc Kesselman, DO
Cardiovascular Disease · Davie, FLNPI 1285685115
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Amgen at 36.4% of the total. Reporting peaked in 2023 at $181 and has fallen 66.4% since, to $61 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in FL, where the typical reported total is $2,774.
Across 17 payments — averaging $23.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$147
- Progentec Diagnostics, Inc.$83
- Kiniksa Pharmaceuticals International, PLC$26
- AstraZeneca$25
- Mallinckrodt Hospital Products Inc.$23
- Gilead$22
- plus $77 from 4 others
What the payments were for
- Food & beverage$403100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 8 | $147 |
| Progentec Diagnostics, Inc. | 1 | $83 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| AstraZeneca | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Gilead | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Radius Health, Inc. | 1 | $20 |
| Pharming Healthcare, Inc. | 1 | $19 |
| Pfizer | 1 | $16 |
How this compares
$403 in reported general payments places this provider in the 15th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 14 | $94,663 |
| Cimzia (2 Pack)Certolizumab Pegol | 13 | $78,262 |
| MethotrexateMethotrexate Sodium | 35 | $1,075 |
| Hydroxychloroquine Sulfate | 15 | $373 |
| Prednisone | 18 | $156 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Davie
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.